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OBJECTIVES This study investigated the incidence of appropriate implantable cardioverter defibrillator
(ICD) interventions for ventricular tachycardia (VT) or ventricular fibrillation (VF) in
patients with idiopathic dilated cardiomyopathy (IDC) and nonsustained VT in the presence
of a left ventricular ejection fraction below 30%, versus in patients with syncope and patients
with a history of VT or VF.
BACKGROUND To date, only limited information is available about the prophylactic use of ICDs in patients
with IDC.
METHODS From January 1993 to July 2000, 101 patients with IDC underwent implantation of ICDs
with electrogram storage capability at our institution. Patients were placed into one of three
groups according to their clinical presentation: asymptomatic or mildly symptomatic
nonsustained VT in the presence of a left ventricular ejection fraction 30% (49 patients,
prophylactic group), unexplained syncope or near syncope (26 patients, syncope group) and
a history of sustained VT or VF (26 patients, VT/VF group).
RESULTS During 36 22 months follow-up, 18 of 49 patients (37%) in the prophylactic group received
appropriate shocks for VT or VF, compared with 8 of 26 patients (31%) in the syncope group
and with 9 of 26 patients (35%) of the VT/VF group. Multivariate Cox analysis of baseline
clinical variables identified left ventricular ejection fraction, atrial fibrillation and a history of
sustained VT or VF as predictors for appropriate ICD interventions during follow-up.
CONCLUSION Patients with IDC and prophylactic ICD implantation for nonsustained VT in the presence
of a left ventricular ejection fraction30% had an incidence of appropriate ICD interventions
similar to that of patients with a history of syncope or sustained VT or VF. These findings
indicate that ICDs may have a role in not only secondary but also primary prevention of
sudden death in IDC. (J Am Coll Cardiol 2002;39:780–7) © 2002 by the American
College of Cardiology Foundation
The implantable cardioverter defibrillator (ICD) has be-
come the therapy of first choice to prevent sudden cardiac
death in high-risk patients who have survived an episode of
a hemodynamically poorly tolerated sustained ventricular
tachycardia (VT) or ventricular fibrillation (VF) in the
absence of a reversible cause (1,2). In addition, prophylactic
ICD therapy has been demonstrated to improve survival in
selected postinfarct patients (3). Unlike in ischemic cardio-
myopathy, arrhythmia risk stratification with regard to
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prophylactic ICD therapy is a completely unsolved issue in
idiopathic dilated cardiomyopathy (IDC) (2,4). Although
electrophysiologic studies currently have a central role in
identifying high-risk patients with coronary disease in
whom prophylactic ICD therapy is indicated (3), the result
of programmed ventricular stimulation has not been found
to be helpful for arrhythmia risk prediction in IDC (5,6).
Two previous studies with small numbers of patients sug-
gest that patients with IDC and unexplained syncope may
benefit from ICD implantation (7,8). Several observational
studies found an increased risk for sudden death in patients
with IDC and nonsustained VT on Holter (9–11). To date,
however, the usefulness of ICD therapy in these patients
remains unknown (12,13). Accordingly, the present study
investigated the incidence of appropriate ICD shocks as
assessed from stored electrograms in patients with IDC,
nonsustained VT on Holter and a left ventricular ejection
fraction 30%, compared with the incidence in ICD
patients with unexplained syncope and to patients with a
history of sustained VT or VF.
METHODS
Patients. The study population consisted of 101 patients
with IDC who underwent implantation of ICDs with
electrogram storage capability and nonthoracotomy lead
systems at our institution between January 1993 and July
2000. Patients were placed in one of three groups according
to their clinical presentations: asymptomatic or mildly
symptomatic nonsustained VT in the presence of a left
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ventricular ejection fraction 30% (49 patients, prophylac-
tic group), unexplained syncope or near syncope (26 pa-
tients, syncope group) and a history of sustained VT or VF
(26 patients, VT/VF group). All patients in the syncope
group were hospitalized after the episode of syncope that
preceded defibrillator implantation and were included in
this study only if the etiology of syncope remained unde-
termined after a thorough evaluation (14). Comprehensive
echocardiographic examinations were performed by one
experienced echocardiographer in all 101 study patients
within one week before ICD implantation using a commer-
cially available system (Sonotron VingMed CFM 700,
Sonotron, Oslo, Norway). Left ventricular end-diastolic
diameter and ejection fraction were measured according to
American Society of Echocardiography guidelines (15).
Three measurements were averaged for each value. To
determine LV ejection fraction, the apical four-chamber
view was optimized for maximum LV areas and frames.
Then the largest and smallest LV cavity size was measured
by tracing the endocardial borders to calculate end-diastolic
and end-systolic volume obtained from paired apical
views—that is, four-chamber view and orthogonal two-
chamber view. The algorithm applied to these measure-
ments was the disk summation method (modified Simpson’s
rule algorithm) (15). In eight patients, in whom echocar-
diographic determination of LV ejection fraction was diffi-
cult due to the inability to accurately trace the endocardial
borders of the largest and smallest LV cavity size, LV
ejection fraction was determined by radionuclide ventricu-
lography for the purpose of this study. In addition to
noninvasive cardiac evaluation, complete left and right heart
cardiac catheterization, including coronary angiography,
had been performed within three months before ICD
implant in 70 patients (69%) and 24  21 months before
ICD implant in the remaining 31 patients (31%). None of
the patients had coronary artery disease diagnosed by
evidence of any coronary stenosis 50% by angiography or
a history of myocardial infarction, systemic arterial hyper-
tension, alcohol abuse, drug dependency, thyroid disease,
malignancies or systemic diseases known to be associated
with dilated cardiomyopathy. In patients in whom coronary
angiography had been performed more than 12 months
before ICD implant, a symptom-limited exercise stress test
was used to screen for newly developed coronary disease. Of
note, diagnostic cardiac catheterization included endomyo-
cardial biopsy in 94 of 101 study patients (93%), which did
not reveal any evidence for active myocarditis or specific
heart muscle disease in any of these patients.
Defibrillator implantation and device programming. All
patients gave written informed consent before ICD implan-
tation. Patients received beta-blocking agents and antiar-
rhythmic drugs at the time of defibrillator implantation on
the basis of their physicians’ clinical judgement. Exclusively,
ICDs with nonthoracotomy lead systems and biphasic
shock waveforms with a maximum shock energy of 27 to 34
J were used and successfully implanted with an intraopera-
tive defibrillation threshold of 11  5 J. All ICD systems
used in this study provided stored intracardiac electrograms
in addition to beat-to-beat intervals of episodes triggering
device therapy (Guidant, St. Paul, Minnesota: models
Ventak P2, Mini2, Mini4, Prizm, Ventak AV; and
Medtronic, Minneapolis, Minnesota: models 7202, 7219,
7220, 7221, 7223, 7227, 7229, 7271, 7272, 7273). In 65 of
101 study patients (64%), the implanted defibrillators were
programmed to single-zone devices for VF detection at
cycle lengths below 307  12 ms (range 330 ms to 290 ms).
In the remaining 36 patients (36%), the implanted defibril-
lators were programmed to two-zone devices for VT detec-
tion at cycle lengths below 319  13 ms (range 350 ms to
300 ms) and for VF detection at cycle lengths below 247 
12 ms (range 300 ms to 240 ms).
The time an arrhythmia needed to persist for VF detec-
tion ranged from one to three seconds in Guidant devices;
the majority of Medtronic devices were programmed to
require 18 out of 24 beats below the programmed VF
detection cycle length in order to initiate capacitor charging
in the VF zone. Based on the preference of the attending
physician and on the result of intraoperative defibrillation
threshold testing, the first programmed shock energy in the
VF zone ranged from 20 to 34 J in the noncommitted mode
in order to avoid shocks for nonsustained VT. All subse-
quent shocks for VF detection were programmed to maxi-
mum shock energy. Of note, all ICDs in this study provided
either ventricular demand pacing (in 95 patients) or dual
chamber demand pacing (in the remaining 6 patients) with
a programmed bradycardia escape rate ranging from 34 to
70 beats/min.
Follow-up. All data of baseline clinical characteristics,
including the results of noninvasive and invasive cardiac
evaluation and implant data, had been collected prospec-
tively in the Marburg Defibrillator Database. Follow-up
started at the time of defibrillator implantation and ended in
December 2000. Follow-up could be completed for all 101
study patients. Patients were followed up primarily in our
defibrillator outpatient clinic in three- to four-month inter-
vals or as soon as possible after spontaneous ICD shocks for
device interrogation and retrieval of stored electrograms. All
stored electrograms of episodes triggering ICD therapy
were classified by two experienced electrophysiologists as
appropriate or inappropriate using previously described
criteria (16–18). Using these criteria, the interobserver
agreement in the present study was 100% for VT or VF with
Abbreviations and Acronyms
ACE  angiotensin converting enzyme
ICD  implantable cardioverter defibrillator
IDC  idiopathic dilated cardiomyopathy
LV  left ventricle
VF  ventricular fibrillation
VT  ventricular tachycardia
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rates 240 beats/min; disagreement occurred in three
arrhythmia episodes with rates 240 beats/min. For the
purpose of this study, these three episodes were subse-
quently classified as supraventricular arrhythmias triggering
inappropriate device therapy.
Statistical analysis. Baseline clinical characteristics of the
prophylactic group, the syncope group and the VT/VF
group were compared using the Kruskal-Wallis test. Event-
free survival probabilities were estimated with the Kaplan-
Meier method, with transplant candidates being censored at
the time of transplantation. Multivariate Cox proportional-
hazards regression analysis was used to evaluate the associ-
ation between the baseline clinical variables and the occur-
rence of appropriate ICD interventions during follow-up.
Because the implant procedure may lead to an exacerbation
of ventricular tachyarrhythmias, episodes of VT or VF
occurring within one week after the operation in four
patients were excluded from further analysis. In addition, we
excluded episodes of VT or VF occurring in five patients
within one week of death; no prognostic benefit can be
derived from ICD shocks with a close time relationship to
death, which was predominantly caused by end-stage heart
failure. The final Cox regression model was built by a
stepwise procedure with a significance level of 0.15 as
criterion for entry into the model. Results are expressed as
mean  SD unless otherwise specified. All p-values re-
ported are two-sided, and a p-value 0.05 was considered
to be statistically significant. SAS software (SAS Institute,
Cary, North Carolina) was used for statistical analyses.
RESULTS
Patient characteristics. All 101 patients with IDC were in
a clinically stable state, with New York Heart Association
classification of I, II or III at the time of ICD implantation
and a mean LV ejection fraction of 25  8% (Table 1). By
definition, all patients in the prophylactic group had an LV
ejection fraction 30% and nonsustained VT on Holter or
telemetry monitoring before ICD implantation. The long-
est episode of nonsustained VT in the prophylactic group
was a mean of 8  5 beats with a mean rate of 172  35
beats/min. Left ventricular ejection fraction was lower in the
49 patients in the prophylactic group, compared with that in
the 26 patients in the syncope group or the 26 patients in
the VT/VF group (22  6% vs. 27  9% and 31  8%,
respectively). Medical therapy at the time of hospital dis-
charge and at follow-up is summarized in Table 2. Of note,
beta-blocker use was similar in all three groups at the time
of hospital discharge; amiodarone was used more frequently
in the VT/VF group.
Appropriate defibrillator interventions. During 36  22
months mean follow-up after ICD implantation, 18 of 49
patients (37%) in the prophylactic group received appropri-
ate ICD interventions for VT or VF, compared with 8 of 26
patients (31%) in the syncope group and 9 of 26 patients
Table 1. Characteristics of the 101 Study Patients at the Time of Cardioverter-
Debrillator Implantation
Characteristic
All
Patients
(n  101)
Prophylactic
Group
(n  49)
Syncope
Group
(n  26)
VT/VF
Group
(n  26)
Mean age, years 51  14 49  13 51  15 55  13
Range 17–75 17–72 23–72 24–75
Male gender (%) 82 (81) 41 (84) 21 (81) 20 (77)
New York Heart Association class (%)
I 4 (4) 1 (2) 1 (4) 2 (8)
II 62 (61) 26 (53) 18 (69) 18 (69)
III 35 (35) 22 (45) 7 (27) 6 (23)
Duration of symptoms, months† 36  45 35  45 33  37 41  51
Symptom duration  12 months (%) 55 (54) 26 (53) 17 (65) 12 (46)
Echocardiographic study
LV end-diastolic diameter, mm 70  8 71  7 69  9 68  7
Range 57–97 58–85 57–97 58–88
LV ejection fraction, % 25  8* 22  6 27  9 31  8
Range 10–45 10–30 13–45 10–45
12-lead electrocardiogram (%)
Atrial fibrillation 21 (21) 9 (18) 4 (15) 8 (31)
Left bundle branch block 32 (32) 14 (29) 7 (27) 11 (42)
Right bundle branch block 1 (1) 1 (2) 0 (0) 0 (0)
Nonsustained VT on Holter or telemetry (%) 82 (81)* 49 (100) 21 (81) 12 (46)
Rate of nonsustained VT, beats/min 173  32 172  35 175  28 170  24
Range 124–295 125–295 124–240 136–230
Length of nonsustained VT, beats/min 8  5 8  5 8  6 8  5
Range 3–34 3–25 3–34 3–16
*p  0.05 for differences among the 3 groups, †including the duration from the time of first diagnosis of IDC in asymptomatic
patients.
LV  left-ventricular; VT  ventricular tachycardia; VF  ventricular fibrillation.
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(35%) of the VT/VF group (Table 3, Figs. 1 and 2A). The
incidence of appropriate ICD shocks for rapid VT or VF
240 beats/min was also similar in the three groups (Fig.
2B). The mean duration of VT or VF episodes triggering
appropriate device therapy from the onset of the arrhythmia
until arrhythmia termination by the device was 10 s  7 s
(median 10 s, range 4 s to 46 s) for VTs with rates 240
beats/min, and 13 s  5 s (median 12 s, range 8 s to 37 s)
for rapid VTs or VF with rates 240 beats/min, without
significant differences among the three groups. The mean
duration from device implant until the first appropriate ICD
intervention was 12 11 months in the prophylactic group,
compared with 9  13 months in the syncope group and 15
 11 months in the VT/VF group. Multivariate Cox
regression analysis of baseline clinical variables identified
left ventricular ejection fraction, atrial fibrillation and a
Table 2. Medication at the Time of Hospital Discharge After Defibrillator Implant and at Most
Recent Follow-Up
All
Patients
(n  101)
Prophylactic
Group
(n  49)
Syncope
Group
(n  26)
VT/VF
Group
(n  26)
Medication at hospital discharge (%)
Digitalis 85 (84) 42 (86) 22 (85) 21 (81)
Diuretics 88 (87) 42 (86) 23 (88) 23 (88)
Angiotensin converting enzyme inhibitors 89 (88) 44 (90) 24 (92) 21 (81)
Angiotensin II receptor antagonists 3 (3) 2 (4) 0 (0) 1 (4)
Spironolactone 5 (5) 2 (4) 1 (4) 2 (8)
-Blockers without d,I-sotalol 32 (32) 16 (33) 7 (27) 9 (35)
D,l-sotalol 6 (6) 1 (2) 2 (8) 3 (12)
Amiodarone 22 (22)* 10 (20) 2 (8) 10 (38)
Class I antiarrhythmic drugs 2 (2) 0 (0) 0 (0) 2 (8)
Medication at follow-up (%)
Digitalis 89 (88) 46 (94) 23 (88) 20 (77)
Diuretics 87 (86) 45 (92) 19 (73) 23 (88)
Angiotensin converting enzyme inhibitors 89 (88) 41 (84) 24 (92) 24 (92)
Angiotensin II receptor antagonists 8 (8) 6 (12) 1 (4) 1 (4)
Spironolactone 24 (24) 13 (27) 6 (23) 5 (19)
-Blockers without D,l-sotalol 49 (49) 30 (61) 9 (35) 10 (38)
D,l-sotalol 8 (8) 2 (4) 3 (12) 3 (12)
Amiodarone 24 (24) 7 (14) 7 (27) 10 (38)
Class I antiarrhythmic drugs 3 (3) 1 (2) 0 (0) 2 (8)
*p  0.05 for differences among the 3 groups.
Table 3. Appropriate and Inappropriate ICD Interventions and Transplant-Free Survival During
Follow-Up
Characteristic
All
Patients
(n  101)
Prophylactic
Group
(n  49)
Syncope
Group
(n  26)
VT/VF
Group
(n  26)
Follow-up duration, months 36  22 35  20 41  23 32  26
Range 3–84 3–79 9–80 7–84
Appropriate ICD Interventions* (%)
Any ICD intervention for VT/VF 35 (35) 18 (37) 8 (31) 9 (35)
2 interventions for VT/VF 29 (29) 15 (31) 8 (31) 6 (23)
1 ICD shock for VT/VF 240 beats/min 27 (27) 12 (24) 8 (31) 7 (27)
Inappropriate ICD Interventions* (%)
Any inappropriate ICD intervention 16 (16) 9 (18) 5 (19) 2 (8)
ICD shocks for AF or SVT 10 (10) 6 (12) 4 (15) 0 (0)
ICD shocks for nonsustained VT 5 (5) 3 (6) 1 (4) 1 (4)
ICD shocks due to electrode fracture 1 (1) 0 (0) 0 (0) 1 (1)
Time to 1st ICD therapy for VT/VF, months 12  11 12  11 9  13 15  13
Range 1–40 1–32 1–40 1–33
Mortality during follow-up (%)
Death from any cause 18 (18) 11 (22) 3 (12) 4 (15)
Death due to progressive heart failure 13 (13) 8 (16) 2 (8) 3 (12)
Sudden cardiac death 1 (1) 1 (2) 0 (0) 0 (0)
Noncardiac death 4 (4) 2 (4) 1 (4) 1 (4)
Heart transplant (%) 11 (11) 5 (10) 4 (15) 2 (8)
*Exclusively episodes as documented by stored electrograms were included for analysis.
AF atrial fibrillation with rapid ventricular response; ICD implantable cardioverter defibrillator; SVT supraventricular
tachycardia; VT  ventricular tachycardia; VF  ventricular fibrillation.
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history of sustained VT or VF before defibrillator implan-
tation as predictors for appropriate ICD interventions
during follow-up, as summarized in Table 4.
Sudden death and transplant-free survival. During 36 
22 months of follow-up, 18 patients died (18%) and 11
patients (11%) underwent successful heart transplant (Table
3, Fig. 2C). Only one patient died suddenly at home, 24
months after prophylactic ICD implantation while waiting
for heart transplantation. Unfortunately, sudden death was
not witnessed in this patient, and the device was not
available for retrieval of stored ECGs after the patient died.
Complications related to ICD therapy. During 36  22
months of follow-up, 29 of 101 study patients (29%) had
one or more of the following complications: inappropriate
shocks (16 patients, 16%), as summarized in Table 3;
bleeding or pocket hematoma (2 patients, 2%); generator
malfunction, including inappropriate charge time prolonga-
tion necessitating generator replacement (4 patients, 4%);
periarthritis humeroscapularis (2 patients, 2%); and lead-
related complications, including endocardial lead migration,
lead fracture or insulation defect (8 patients, 8%). No
patient died perioperatively (30-day). In addition, no ICD
infection and no thromboembolic complications were ob-
served at implant and during follow-up.
DISCUSSION
This is the first study to report the incidence of appropriate
ICD interventions exclusively based on stored electrograms
by the device in a relatively large patient population with
IDC and prophylactic ICD therapy compared to patients
with unexplained syncope and patients with a history of
sustained VT or VF. The major finding of our study is that
patients with IDC in whom prophylactic ICD implantation
was performed for asymptomatic or only mildly symptom-
atic nonsustained VT in the presence of a left ventricular
ejection fraction 30% had a similar incidence of appropri-
ate ICD interventions as did patients with unexplained
syncope or patients with a history of sustained VT or VF.
The results of multivariate Cox regression analysis of
baseline clinical variables strongly suggest that the compa-
rable incidence of appropriate ICD interventions in the
prophylactic group and the VT/VF group is due to the
significantly lower LV ejection fraction in the prophylactic
group compared with that in the VT/VF group. The low
LV ejection fraction appears to have outweighed the history
of sustained VT or VF as a risk factor for subsequent
adequate ICD interventions in this patient population.
Because not every episode of spontaneous sustained VT or
VF would lead to sudden cardiac death in the absence of
device therapy, Bo¨cker and colleagues (19,20) have previ-
ously suggested using the occurrence of ICD shocks for fast
VT or VF 240 beats/min to estimate the potential benefit
from ICD therapy in different patient groups. Of note,
analysis of stored electrogram data restricted to rapid VT or
VF in our study also revealed a similar incidence of these
rapid ventricular tachyarrhythmias in the prophylactic group
versus in the syncope group and the VT/VF group (Fig.
2B).
Prior studies in patients with IDC and a history of VT or
VF. Three prior studies focused on the outcome of patients
with IDC and a history of sustained VT or VF treated by
implantable defibrillators (21–23). Fazio et al. (21) found
appropriate ICD shocks in 24 of 39 patients (62%) with
IDC and a history of sustained VT or VF during a mean
follow-up of 30 months. Grimm et al. (22) observed
appropriate shocks in 25 of 49 patients (51%) with IDC and
a history of VT or VF (n  43) or syncope in the presence
of nonsustained VT (n  6) during a mean follow-up of 25
months. Finally, Ba¨nsch and coworkers (23) noted appro-
priate ICD interventions in 73 of 106 patients (69%) with
IDC during 33 23 months follow-up. In contrast to these
three previous reports (21–23), only 9 of 26 patients (35%)
Figure 1. Stored electrogram (25 mm/s) of spontaneous ventricular tachycardia terminated by a 31 J shock in a patient with idiopathic dilated
cardiomyopathy and prophylactic defibrillator implantation. VF  ventricular fibrillation.
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with IDC and a history of VT or VF received appropriate
ICD interventions during a mean follow-up of 32 months
in the present study. This discrepancy may, in part, be due
to differences in patient selection, as well as concomitant
medical therapy in these three studies. In addition, the
definition of appropriate shocks in the present study was
based exclusively on electrograms stored by the device;
previous investigators had to rely to a great extent on
symptoms preceding spontaneous shocks to define appro-
priate shocks.
Prior studies in patients with IDC and unexplained
syncope. Knight et al. (7) observed appropriate ICD
shocks in 7 of 14 patients (50%) with IDC and unexplained
syncope during 24 months follow-up, compared with 8 of
19 patients (42%) with IDC and a history of cardiac arrest
during 45 months follow-up. Fonarow et al. (8) found
appropriate shocks in 10 of 25 patients (40%) with IDC and
unexplained syncope during 22 months follow-up. In con-
trast to these two previous studies, a slightly lower incidence
of appropriate ICD interventions for VT or VF was found
in 8 of 26 patients (31%) with unexplained syncope during
41 months follow-up in the present study.
Studies using prophylactic ICD implantation in IDC.
Levine et al. (12) observed appropriate ICD shocks in eight
of nine patients (89%) with IDC in whom prophylactic
ICD implantation had been performed for asymptomatic
nonsustained VT in the presence of a left ventricular
ejection fraction of 28  14% during 35 months of
follow-up. In contrast to the study of Levine et al. (12), we
observed appropriate ICD interventions in 37% of patients
with prophylactic ICD therapy for asymptomatic or only
mildly symptomatic nonsustained VT and an ejection frac-
tion of 22  6%. This discrepancy may be due to the larger
number of patients in our study, as well as to the fact that
Figure 2. Kaplan-Meier curves showing the event-free survival rates for: (A) appropriate implantable cardioverter defibrillator (ICD) interventions for any
ventricular tachycardia (VT) or ventricular fibrillation (VF) as documented by stored electrograms; (B) appropriate ICD shocks exclusively for rapid VT
or VF with a mean rate 240 beats/min; (C) transplant-free survival.
785JACC Vol. 39, No. 5, 2002 Grimm et al.
March 6, 2002:780–7 Defibrillator Therapy in Dilated Cardiomyopathy
only episodes with stored electrograms showing VT or VF
triggering device therapy were accepted as appropriate ICD
interventions in our study. Recently, the preliminary results
of the AMIOVIRT trial have been reported (4). A multi-
center, randomized trial, AMIOVIRT examined the total
mortality rate associated with amiodarone versus ICD
therapy in patients with nonischemic dilated cardiomyopa-
thy, an ejection fraction 35% and asymptomatic nonsus-
tained VT. The trial was stopped early after 102 patients
were randomized because the number of patients surviving
during 20  13 months follow-up were similar in the
amiodarone and ICD treatment groups (4).
Study limitations. The study had some limitations. 1) It
was an uncontrolled observational study with the incidence
of appropriate ICD interventions for VT or VF and ICD
interventions for rapid VT or VF with rates240 beats/min
as surrogate endpoints for a potential benefit from defibril-
lator therapy, as previously suggested by Bo¨cker et al.
(19,20). This study does not have the same value or power
as a properly designed, randomized, multicenter study with
total mortality as primary end point in order to prove that
prophylactic ICD implantation is warranted in patients with
IDC and nonsustained VT in the presence of a low LV
ejection fraction. 2) Quality of life issues and cost-
effectiveness analyses have not been performed in this study.
3) Because this study started in January 1993, the use of
beta-blockers was not included as standard heart failure
therapy in the majority of patients at study entry. In
addition, beta-blocker dosing was not standardized in the
majority of patients but varied considerably between
patients according to the attending physician’s prefer-
ence. Therefore, we cannot make any valid conclusions
with regard to the value of beta-blocker therapy for
arrhythmia risk reduction in this patient population with
IDC.
Clinical implications. The present study showed that a
substantial number of patients with IDC in whom prophy-
lactic ICDs were implanted for asymptomatic or only mildly
symptomatic nonsustained VT in the presence of an ejection
fraction 30% had appropriate discharges during 36
months mean follow-up. In addition, multivariate analysis
of baseline clinical variables suggests that the comparable
incidence of appropriate ICD interventions in the prophy-
lactic group and the VT/VF group is due to the significantly
lower LV ejection fraction in the prophylactic group com-
pared to the VT/VF group, which appears to have out-
weighed the history of sustained VT or VF as a risk factor
for subsequent adequate ICD interventions. Thus, our data
support the view that ICD implantation may be a valuable
tool for both secondary and primary prevention of sudden
death in IDC. It is also important, however, to recognize
that ICD therapy is expensive and not free of complications
Table 4. Association Between Baseline Clinical Characteristics and Appropriate Defibrillator
Interventions During Follow-Up
VT/FV
During FU
(n  35)
No
VT/VF
(n  66)
Multivariate Cox
Regression Analysis
p Value
Relative
Risk 95% CI
Clinical characteristics at implant
Age, years 52  13 50  14 NS
Male gender (%) 30 (86) 52 (79) NS
NHYA class III 13 (37) 22 (33) NS
Indication for ICD implant
Prophylactic implant 18 (51) 31 (47) NS
Unexplained syncope 8 (23) 18 (27) NS
History of sustained VT/VF 9 (26) 17 (26) 0.036 2.85 1.07 to 7.58
Antiarrhythmics at hospital discharge
-blockers without sotalol 8 (23) 24 (36) NS
D,l-sotalol 3 (9) 3 (5) NS
Amiodarone 8 (23) 14 (21) NS
Antiarrhythmics at follow-up
-blockers without sotalol 15 (43) 34 (52) NS
D,l-sotalol 1 (3) 7 (11) NS
Amiodarone 13 (37) 11 (17) NS
Echocardiographic study at implant
LV end-diastolic diameter, mm 70  6 69  6 NS
LV ejection fraction, % 23  7 27  9 0.0002 1.76* 1.31 to 2.38*
3.11† 1.71 to 5.66†
Electrocardiography at implant (%)
Atrial fibrillation 11 (31) 10 (15) 0.009 2.76 1.28 to 5.97
Left bundle branch block 10 (29) 22 (33) NS
Nonsustained VT on Holter or telemetry 31 (89) 51 (77) NS
*Relative risk and 95% confidence interval per 5% decrease of LV ejection fraction. †Relative risk and 95% confidence interval
per 10% decrease of LV ejection fraction.
CI  confidence interval; FU  follow-up; ICD  implantable cardioverter defibrillator; NYHA  New York Heart
Association; LV  left ventricular; VT/VF  ventricular tachycardia or fibrillation.
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(24). Therefore, the results of properly designed, random-
ized, multicenter studies (13,25,26) are needed before any
valid recommendations with regard to prophylactic ICD
implantation in IDC can be made. In addition, several
noninvasive strategies for arrhythmia risk stratification have
recently been introduced, which may allow for a more
precise selection of patients who may benefit most from
prophylactic ICD implantation (27).
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